Studies have identified a number of specific pathological processes and proteins in necroptosis. Therefore, it is an important research strategy to regulate these pathological processes and proteins and thus achieve a therapeutic effect on stroke. Although proteins such as the tumor necrosis factor (TNF) family play an important role in necrophagy, they are not used as a target for regulating necroptosis because they are involved in various physiological and pathological activities of the body. Therefore, Ace Therapeutics offers a comprehensive service to accelerate the development of stroke drugs targeting necroptosis.
Although some important targets have been identified in the process of necrotizing targeting, we need to further explore the specific pathological process of necroptosis and find more specific targets to increase the chance of successful stroke drug development.
We construct a target identification and identification platform for necroptosis process, and provide different in vitro and in vivo models of necroptosis to ensure the accuracy and scientificity of the study.
RIP1, RIP3, and MLKL are proteins specific to necroptosis. Therefore, screening for necroptosis regulators against these three proteins has a very high specificity for treating stroke by regulating necroptosis. With this in mind, Ace Therapeutics has established a specific virtual screening platform to screen for regulators targeting these three protein-related pathways.
Preclinical pharmacological activity evaluation of the screened candidate necroptosis modulators against stroke is performed to determine the therapeutic effects and specific mechanisms of action of the candidates against stroke. Ace Therapeutics provides a comprehensive pharmacological activity evaluation and pharmacokinetic evaluation service to accelerate your stroke drug development studies targeting necrotizing apoptosis.
In addition, we provide other services related to the development of stroke drugs targeting necroptosis process. If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.